LEAP, NOK were just tip of the iceberg. With AFFY their losses will be unbearable.
Why, in case of a buyout by Takeda the PPS will be atleast 5 X.
In case of product re-introduction announcement it would be 8 -10 X.
Takeda is doing the investigation and resolution? Do you think they will come back and say "The product is worthless, we are withdrawing from the market?" No way folks.
All ESA's is applied to fragile patients (CKD- Chronic Kidney disease-dialysis patient - Imagine how sick these people are as sick as GEEWEEPEE, LOL!) and all the medications cause these reactions. In O's case already a Warning label exists, when this reaction occurs there are few protocols to be followed including EPI-PEN administration.
It is all coming to whether FMS did the right thing? If so how soon and why it did not work? The solutions starts from there.
Takeda will come out with a patient population for whom O is safe and for whom it would be problematic. For those problematic population they will do the administration either subcutaneous or in a safe hospital setting to ensure nothing untoward happens.
This is a blockbuster for Takeda and they are not abandoning an APPROVED DRUG folks!
The lesson being I wish I was able to short more AFFY. Retail cannot short AFFY, at least at TD Ameritrade, in the ordinary course of business. There is an exception via prior arrangement: You own in the money puts at expiration, and you bought AFFY to cover those puts before the expiration of the puts.